BioCentury
ARTICLE | Company News

Calypso Biotech debuts to develop Merck Serono's IBD R&D

March 5, 2013 2:12 AM UTC

The Merck Serono S.A. division of Merck KGaA (Xetra:MRK) launched Calypso Biotech to develop Merck Serono's preclinical R&D portfolio for gastrointestinal immunological disorders. The newco will continue R&D of undisclosed preclinical antibody programs from Merck Serono in inflammatory bowel diseases (IBD). Merck Serono will invest EUR 2.5 million ($3.3 million) in seed funding. ...